TFF Pharmaceuticals (NASDAQ:TFFP) Given New $44.00 Price Target at Roth Mkm

TFF Pharmaceuticals (NASDAQ:TFFP) had its target price lowered by investment analysts at Roth Mkm from $56.00 to $44.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock.

TFF Pharmaceuticals Price Performance

Shares of TFF Pharmaceuticals stock traded down $0.52 on Thursday, reaching $6.07. The company had a trading volume of 37,819 shares, compared to its average volume of 25,371. The firm’s 50-day moving average price is $6.69 and its two-hundred day moving average price is $7.33. TFF Pharmaceuticals has a 1 year low of $4.55 and a 1 year high of $21.25.

Institutional Investors Weigh In On TFF Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its stake in shares of TFF Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 69,929 shares of the company’s stock worth $441,000 after acquiring an additional 5,251 shares during the last quarter. UBS Group AG lifted its stake in shares of TFF Pharmaceuticals by 12.3% during the 2nd quarter. UBS Group AG now owns 92,177 shares of the company’s stock worth $521,000 after acquiring an additional 10,123 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of TFF Pharmaceuticals by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 864,983 shares of the company’s stock worth $5,458,000 after acquiring an additional 52,813 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth approximately $60,000. Finally, Renaissance Technologies LLC bought a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth approximately $76,000. 15.25% of the stock is owned by institutional investors.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.